Search Results - "Smit, Egbert F"

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics by Best, Myron G., Sol, Nik, Kooi, Irsan, Tannous, Jihane, Westerman, Bart A., Rustenburg, François, Schellen, Pepijn, Verschueren, Heleen, Post, Edward, Koster, Jan, Ylstra, Bauke, Ameziane, Najim, Dorsman, Josephine, Smit, Egbert F., Verheul, Henk M., Noske, David P., Reijneveld, Jaap C., Nilsson, R. Jonas A., Tannous, Bakhos A., Wesseling, Pieter, Wurdinger, Thomas

“…Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic and local responses to tumor growth, thereby altering their RNA…”
Get full text

Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine by Dijkstra, Krijn K., Monkhorst, Kim, Schipper, Luuk J., Hartemink, Koen J., Smit, Egbert F., Kaing, Sovann, de Groot, Rosa, Wolkers, Monika C., Clevers, Hans, Cuppen, Edwin, Voest, Emile E.

“…Clinical implementation of tumor organoids for personalized medicine requires that pure tumor organoids can be reliably established. Here, we present our…”
Get full text

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort by Mazières, Julien, Zalcman, Gérard, Crinò, Lucio, Biondani, Pamela, Barlesi, Fabrice, Filleron, Thomas, Dingemans, Anne-Marie C, Léna, Hervé, Monnet, Isabelle, Rothschild, Sacha I, Cappuzzo, Federico, Besse, Benjamin, Thiberville, Luc, Rouvière, Damien, Dziadziuszko, Rafal, Smit, Egbert F, Wolf, Jurgen, Spirig, Christian, Pecuchet, Nicolas, Leenders, Frauke, Heuckmann, Johannes M, Diebold, Joachim, Milia, Julie D, Thomas, Roman K, Gautschi, Oliver

“…Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains. In…”
Get full text

Dabrafenib in patients with BRAFV600E -positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial by Planchard, David, MD, Kim, Tae Min, MD, Mazieres, Julien, Prof, Quoix, Elisabeth, Prof, Riely, Gregory, MD, Barlesi, Fabrice, Prof, Souquet, Pierre-Jean, MD, Smit, Egbert F, Prof, Groen, Harry J M, Prof, Kelly, Ronan J, MD, Cho, B C, MD, Socinski, Mark A, Prof, Pandite, Lini, MD, Nase, Christine, BSN, Ma, Bo, PhD, D'Amelio, Anthony, PhD, Mookerjee, Bijoyesh, MD, Curtis, C Martin, BS, Johnson, Bruce E, Prof

“…Summary Background Activating BRAFV600E (Val600Glu) mutations are found in about 1–2% of lung adenocarcinomas, which might provide an opportunity for targeted…”
Get full text

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3 by Sun, Chong, Hobor, Sebastijan, Bertotti, Andrea, Zecchin, Davide, Huang, Sidong, Galimi, Francesco, Cottino, Francesca, Prahallad, Anirudh, Grernrum, Wipawadee, Tzani, Anna, Schlicker, Andreas, Wessels, Lodewyk F A, Smit, Egbert F, Thunnissen, Erik, Halonen, Pasi, Lieftink, Cor, Beijersbergen, Roderick L, Di Nicolantonio, Federica, Bardelli, Alberto, Trusolino, Livio, Bernards, Rene

“…There are no effective therapies for the ~30% of human malignancies with mutant RAS oncogenes. Using a kinome-centered synthetic lethality screen, we find that…”
Get full text

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs by Van der Veldt, Astrid A.M., Lubberink, Mark, Bahce, Idris, Walraven, Maudy, de Boer, Michiel P., Greuter, Henri N.J.M., Hendrikse, N. Harry, Eriksson, Jonas, Windhorst, Albert D., Postmus, Pieter E., Verheul, Henk M., Serné, Erik H., Lammertsma, Adriaan A., Smit, Egbert F.

“…Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs,…”
Get full text

Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung Cancer by Lagerwaard, Frank J., M.D., Ph.D, Haasbeek, Cornelis J.A., M.D, Smit, Egbert F., M.D., Ph.D, Slotman, Ben J., M.D., Ph.D, Senan, S., M.R.C.P., F.R.C.R., Ph.D

“…Purpose High local control rates can be achieved using stereotactic radiotherapy in Stage I non–small-cell lung cancer (NSCLC), but reports have suggested that…”
Get full text

Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation by van Velden, Floris H. P., Kramer, Gerbrand M., Frings, Virginie, Nissen, Ida A., Mulder, Emma R., de Langen, Adrianus J., Hoekstra, Otto S., Smit, Egbert F., Boellaard, Ronald

“…Purpose To assess (1) the repeatability and (2) the impact of reconstruction methods and delineation on the repeatability of 105 radiomic features in…”
Get full text

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC by Manegold, Christian, Dingemans, Anne-Marie C, Gray, Jhanelle E, Nakagawa, Kazuhiko, Nicolson, Marianne, Peters, Solange, Reck, Martin, Wu, Yi-Long, Brustugun, Odd Terje, Crinò, Lucio, Felip, Enriqueta, Fennell, Dean, Garrido, Pilar, Huber, Rudolf M, Marabelle, Aurélien, Moniuszko, Marcin, Mornex, Françoise, Novello, Silvia, Papotti, Mauro, Pérol, Maurice, Smit, Egbert F, Syrigos, Kostas, van Meerbeeck, Jan P, van Zandwijk, Nico, Yang, James Chih-Hsin, Zhou, Caicun, Vokes, Everett

“…Over the past few years, there have been considerable advances in the treatments available to patients with metastatic or locally advanced NSCLC, particularly…”
Get more information

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial by Huber, Rudolf M, Hansen, Karin H, Paz-Ares Rodríguez, Luis, West, Howard L, Reckamp, Karen L, Leighl, Natasha B, Tiseo, Marcello, Smit, Egbert F, Kim, Dong-Wan, Gettinger, Scott N, Hochmair, Maximilian J, Kim, Sang-We, Langer, Corey J, Ahn, Myung-Ju, Kim, Edward S, Kerstein, David, Groen, Harry J M, Camidge, D Ross

“…We report updated data from a phase 2 randomized study evaluating brigatinib in crizotinib-refractory anaplastic lymphoma kinase-positive NSCLC. Patients were…”
Get more information

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients by Semenova, Ekaterina A., Kwon, Min-chul, Monkhorst, Kim, Song, Ji-Ying, Bhaskaran, Rajith, Krijgsman, Oscar, Kuilman, Thomas, Peters, Dennis, Buikhuisen, Wieneke A., Smit, Egbert F., Pritchard, Colin, Cozijnsen, Miranda, van der Vliet, Jan, Zevenhoven, John, Lambooij, Jan-Paul, Proost, Natalie, van Montfort, Erwin, Velds, Arno, Huijbers, Ivo J., Berns, Anton

“…Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective treatment is available to date. Mouse models of SCLC based on the…”
Get full text

Outcomes of Stereotactic Ablative Radiotherapy in Patients With Potentially Operable Stage I Non-Small Cell Lung Cancer by Lagerwaard, Frank J., M.D., Ph.D, Verstegen, Naomi E., B.Sc, Haasbeek, Cornelis J.A., M.D., Ph.D, Slotman, Ben J., M.D., Ph.D, Paul, Marinus A., M.D., Ph.D, Smit, Egbert F., M.D., Ph.D, Senan, Suresh, Ph.D., F.R.C.R., M.R.C.P

“…Background Approximately two-thirds of patients with early-stage non-small-cell lung cancer (NSCLC) in The Netherlands currently undergo surgical resection. As…”
Get full text

Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach by Popat, Sanjay, Navani, Neal, Kerr, Keith M., Smit, Egbert F., Batchelor, Timothy J.P., Van Schil, Paul, Senan, Suresh, McDonald, Fiona

“…Non‐small cell lung cancer (NSCLC) accounts for approximately one in five cancer‐related deaths, and management requires increasingly complex decision making…”
Get full text

Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? by Derks, Jules L, van Suylen, Robert Jan, Thunnissen, Erik, den Bakker, Michael A, Groen, Harry J, Smit, Egbert F, Damhuis, Ronald A, van den Broek, Esther C, Speel, Ernst-Jan M, Dingemans, Anne-Marie C

“…Pulmonary large cell neuroendocrine carcinoma (LCNEC) is rare. Chemotherapy for metastatic LCNEC ranges from small cell lung carcinoma (SCLC) regimens to…”
Get full text

A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer by Abedian Kalkhoran, Hanieh, Zwaveling, Juliëtte, Storm, Bert N, van Laar, Sylvia A, Portielje, Johanneke Ea, Codrington, Henk, Luijten, Dieuwke, Brocken, Pepijn, Smit, Egbert F, Visser, Loes E

“…This study was designed to investigate the impact of age on the effectiveness and immune-related adverse events (irAEs) of programmed death-(ligand)1 [PD-(L)1]…”
Get full text

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting by Boosman, René J., Jebbink, Merel, Veldhuis, Wouter B., Groenland, Stefanie L., van Veggel, Bianca A. M. H., Moeskops, Pim, de Langen, Adrianus J., Beijnen, Jos H., Smit, Egbert F., Huitema, Alwin D. R., Steeghs, Neeltje

“…Background Osimertinib, an irreversible inhibitor of the epidermal growth factor receptor (EGFR) is an important drug in the treatment of EGFR-mutation…”
Get full text

Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer by Hummelink, Karlijn, van der Noort, Vincent, Muller, Mirte, Schouten, Robert D, van den Heuvel, Michel M, Thommen, Daniela S, Smit, Egbert F, Meijer, Gerrit A, Monkhorst, Kim

“…The efficacy of PD-1 blocking agents in advanced NSCLC has shown prolonged effectiveness, but only in a minority of patients. Multiple biomarkers have been…”
Get full text

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer by de Bruin, Elza C, Cowell, Catherine, Warne, Patricia H, Jiang, Ming, Saunders, Rebecca E, Melnick, Mary Ann, Gettinger, Scott, Walther, Zenta, Wurtz, Anna, Heynen, Guus J, Heideman, Daniëlle A M, Gómez-Román, Javier, García-Castaño, Almudena, Gong, Yixuan, Ladanyi, Marc, Varmus, Harold, Bernards, René, Smit, Egbert F, Politi, Katerina, Downward, Julian

“…Activating mutations in the EGF receptor (EGFR) are associated with clinical responsiveness to EGFR tyrosine kinase inhibitors (TKI), such as erlotinib and…”
Get more information

Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: A case report by Mellema, Wouter W, Burgers, Sjaak A, Smit, Egbert. F

“…Highlights • We report a striking tumor flare after start of treatment with sorafenib. • Weak RAF inhibition by sorafenib may possibly contribute to a…”
Get full text

Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trial by Louie, Alexander V, van Werkhoven, Erik, Chen, Hanbo, Smit, Egbert F, Paul, Marinus A, Widder, Joachim, Groen, Harry J.M, van den Borne, Ben E.E.M, De Jaeger, Katrien, Slotman, Ben J, Senan, Suresh

“…Abstract We report quality of life and indirect costs from patient reported outcomes from the ROSEL randomized control trial comparing stereotactic ablative…”
Get full text